JP6900596B2 - 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 - Google Patents

赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 Download PDF

Info

Publication number
JP6900596B2
JP6900596B2 JP2018528106A JP2018528106A JP6900596B2 JP 6900596 B2 JP6900596 B2 JP 6900596B2 JP 2018528106 A JP2018528106 A JP 2018528106A JP 2018528106 A JP2018528106 A JP 2018528106A JP 6900596 B2 JP6900596 B2 JP 6900596B2
Authority
JP
Japan
Prior art keywords
hba1c
chlorite
diabetes
treatment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018528106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523711A (ja
JP2018523711A5 (enExample
Inventor
マラプライグサバン、パイブーン
− ウィルヘルム キューネ、フリードリヒ
− ウィルヘルム キューネ、フリードリヒ
Original Assignee
フリードリッヒ − ヴィルヘルム キューネ
フリードリッヒ − ヴィルヘルム キューネ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フリードリッヒ − ヴィルヘルム キューネ, フリードリッヒ − ヴィルヘルム キューネ filed Critical フリードリッヒ − ヴィルヘルム キューネ
Publication of JP2018523711A publication Critical patent/JP2018523711A/ja
Publication of JP2018523711A5 publication Critical patent/JP2018523711A5/ja
Priority to JP2021078253A priority Critical patent/JP2021130664A/ja
Application granted granted Critical
Publication of JP6900596B2 publication Critical patent/JP6900596B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2018528106A 2015-08-20 2016-08-22 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 Active JP6900596B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078253A JP2021130664A (ja) 2015-08-20 2021-05-06 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207774P 2015-08-20 2015-08-20
US62/207,774 2015-08-20
PCT/IB2016/055011 WO2017029648A1 (en) 2015-08-20 2016-08-22 Use of chlorite to treat red blood cell diseases and indications mediated thereby

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078253A Division JP2021130664A (ja) 2015-08-20 2021-05-06 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用

Publications (3)

Publication Number Publication Date
JP2018523711A JP2018523711A (ja) 2018-08-23
JP2018523711A5 JP2018523711A5 (enExample) 2019-10-03
JP6900596B2 true JP6900596B2 (ja) 2021-07-07

Family

ID=56896735

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018528106A Active JP6900596B2 (ja) 2015-08-20 2016-08-22 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用
JP2021078253A Pending JP2021130664A (ja) 2015-08-20 2021-05-06 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078253A Pending JP2021130664A (ja) 2015-08-20 2021-05-06 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用

Country Status (6)

Country Link
US (1) US11813234B2 (enExample)
EP (1) EP3337489B1 (enExample)
JP (2) JP6900596B2 (enExample)
CN (1) CN108135930A (enExample)
RU (1) RU2018109574A (enExample)
WO (1) WO2017029648A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112168841A (zh) * 2019-07-05 2021-01-05 卢序 一种增加人一氧化氮生物利用度的方法
CN112386606A (zh) * 2019-08-19 2021-02-23 卢序 一种有第二信使作用增加积极氧化压力的氧化剂的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754928B2 (en) 1997-10-06 2002-11-28 Oxo Chemie Ag Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
US20040224306A1 (en) 1999-11-30 2004-11-11 Frederich-Wilhelm Kuhne Evaluating and predicting clinical outcomes by gene expression analysis
EP1558237A4 (en) * 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED BLOOD SUGAR CONTROL F RPRU-DIABETES AND / OR DIABETES TYPE II USING DOCOSAHEXAENSURE
EP2081021A4 (en) * 2006-10-16 2014-07-23 Sekisui Chemical Co Ltd HEMOGLOBIN DETERMINATION PROCESS
WO2008145376A1 (en) 2007-06-01 2008-12-04 Dimethaid Ag Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
US20140287064A1 (en) * 2009-04-28 2014-09-25 Karen G. Swenholt Compositions for improving the appearance and/or treating fungal infections of nails, mucus membranes and the integument
EA201290041A1 (ru) 2009-08-06 2012-07-30 Ньюралтус Фармасьютикалс, Инк. Лечение расстройств, связанных с макрофагами
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
RU2014130080A (ru) 2011-12-22 2016-02-10 Нуво Рисерч Гмбх Липосомальные композиции хлоритов или хлоратов
CN104519890A (zh) * 2012-01-19 2015-04-15 Ibt美国公司 四氯十氧(tcdo)的治疗应用
US8748744B2 (en) * 2012-06-28 2014-06-10 Hubbell Incorporated Electrical box extender assembly
CA2945179A1 (en) * 2014-05-16 2015-11-19 Michael S. Mcgrath Methods and compositions for treatment of macrophage-related disorders

Also Published As

Publication number Publication date
JP2021130664A (ja) 2021-09-09
CA2995659A1 (en) 2017-02-23
RU2018109574A (ru) 2019-09-23
JP2018523711A (ja) 2018-08-23
RU2018109574A3 (enExample) 2020-02-27
US11813234B2 (en) 2023-11-14
US20180243334A1 (en) 2018-08-30
EP3337489A1 (en) 2018-06-27
WO2017029648A1 (en) 2017-02-23
BR112018003227A2 (pt) 2018-09-25
CN108135930A (zh) 2018-06-08
EP3337489B1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
O’Hara et al. Applications of SGLT2 inhibitors beyond glycaemic control
Hoang et al. Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection
Hudson et al. Pharmacokinetic data support 6-hourly dosing of intravenous vitamin C to critically ill patients with septic shock
Verove et al. Effect of the correction of metabolic acidosis on nutritional status in elderly patients with chronic renal failure
JP5475671B2 (ja) ピロホスフェートを含む滅菌透析溶液
KR20200037358A (ko) 지방간 질환 및 지방간염의 치료에서의 glp-1/글루카곤 수용체 작용제
JP2021130664A (ja) 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用
Mehrotra Nutritional issues in peritoneal dialysis patients: how do they differ from that of patients undergoing hemodialysis?
EP3982947A1 (en) Methods and compositions for improving outcomes of cancer patients
Chao A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
Chao Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
Dahdah et al. Intravenous iron dextran treatment in predialysis patients with chronic renal failure
WO2019043613A1 (en) SODIUM-GLUCOSE COTRANSPORTING INHIBITORS (SGLT) FOR ENHANCED PERITONEAL DIALYSIS
Schmid et al. New strategies for managing anemia of chronic kidney disease
Nichol Restrictive red blood cell transfusion strategies in critical care: does one size really fit all?
JP2021510157A (ja) 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用
BR112018003227B1 (pt) Uso de clorito para tratar doenças dos glóbulos vermelhos e indicações mediadas desta forma
RU2649760C1 (ru) Способ лечения острого инфаркта миокарда с подъемом сегмента ST, осложненного кардиогенным шоком
Sharif Treatment options for post-transplantation diabetes mellitus
Horton et al. In adults with severe acute GI bleeding, tranexamic acid did not reduce death due to bleeding at 5 days
Macdougall Experience with intravenous iron in nephrology
GÜLDAL et al. Hypercalemıa In The Emergency Department
Pecoits-Filho et al. Clinical trial experiences with Physioneal™
Bhavani et al. Emerging Therapies in Anemia: From Iron Supplementation to Gene Editing
Kvitne Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210405

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210430

R150 Certificate of patent or registration of utility model

Ref document number: 6900596

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250